Bruce Cree, AAN 2022: Disability improvements with ublituximab in relapsing multiple sclerosis – Phase 3 ULTIMATE I and II trials

Ublituximab is a novel glycoengineered monoclonal antibody treatment under investigation for relapsing remitting multiple sclerosis. Prof Bruce Cree (UCSF Multiple Sclerosis Centre, San Francisco, CA, USA) discusses the phase 3 ULTIMATE I and II studies, and the positive results from the tertiary analysis of the data that investigated disability improvements in patients with relapsing multiple sclerosis.

The abstract entitled ‘Disability Improvements With Ublituximab in Relapsing Multiple Sclerosis (RMS): Expanded Disability Status Scale (EDSS), 9-Hole Peg Test (9-HPT), and Timed 25-Foot Walk (T25FW) Evaluations From the Phase 3 ULTIMATE I and II Studies’ was presented at the American Academy of Neurology (AAN) annual meeting, April 2-7, 2022.

View more content from Prof. Bruce Cree:

Bruce Cree, AAN 2022: Bruton tyrosine kinase inhibitors in multiple sclerosis – Key clinical highlights

Bruce Cree, AAN 2022: Ublituximab and its potential use in the treatment of relapsing multiple sclerosis

Questions:

1. What did the ULTIMATE I and II studies and the tertiary analysis teach us about the efficacy and safety of ublituximab in relapsing multiple sclerosis? (0:16)
2. Were there any additional findings from the analysis? (2:12)
3. What has this analysis taught us about the importance of confirmed disability improvement (CDI) in clinical trials for MS therapies? (4:01)

Disclosures: 

Support:  Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of AAN 2022